Metraipolis › archive › dc_602adfe4601c

Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants — Europe PMC PMID:42389543

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42389543
DOI
10.3389/fimmu.2026.1793368
License (as archived)
solo-consultazione
Archived
2026-10-19T08:59:04.851Z
SHA-256 of the archived text
5a37d167e66c54bc8b166ebd2036ae409b5c217bf897c8c918ad12c4464687a7
Stable URL of this page
https://metraipolis.com/documento/dc_602adfe4601c

How to cite

Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants — Europe PMC PMID:42389543 — Europe PMC (en), https://europepmc.org/article/MED/42389543 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_602adfe4601c (Metraipolis archive dc_602adfe4601c, sha256 5a37d167e66c54bc8b166ebd2036ae409b5c217bf897c8c918ad12c4464687a7)
BibTeX
@misc{dc602adfe4601c,
  title = {Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants — Europe PMC PMID:42389543},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42389543},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_602adfe4601c; sha256 5a37d167e66c54bc8b166ebd2036ae409b5c217bf897c8c918ad12c4464687a7},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42389543. Agents can read the archived copy with the MCP tool read_document.